389 related articles for article (PubMed ID: 16371039)
1. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.
Snyder E; McCullough J; Slichter SJ; Strauss RG; Lopez-Plaza I; Lin JS; Corash L; Conlan MG;
Transfusion; 2005 Dec; 45(12):1864-75. PubMed ID: 16371039
[TBL] [Abstract][Full Text] [Related]
2. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light.
Murphy S; Snyder E; Cable R; Slichter SJ; Strauss RG; McCullough J; Lin JS; Corash L; Conlan MG;
Transfusion; 2006 Jan; 46(1):24-33. PubMed ID: 16398727
[TBL] [Abstract][Full Text] [Related]
3. Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial.
Pineda A; McCullough J; Benjamin RJ; Cable R; Strauss RG; Burgstaler E; Porter S; Lin L; Metzel P; Conlan MG;
Transfusion; 2006 Apr; 46(4):562-71. PubMed ID: 16584432
[TBL] [Abstract][Full Text] [Related]
4. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.
Slichter SJ; Raife TJ; Davis K; Rheinschmidt M; Buchholz DH; Corash L; Conlan MG
Transfusion; 2006 May; 46(5):731-40. PubMed ID: 16686840
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.
Janetzko K; Cazenave JP; Klüter H; Kientz D; Michel M; Beris P; Lioure B; Hastka J; Marblie S; Mayaudon V; Lin L; Lin JS; Conlan MG; Flament J
Transfusion; 2005 Sep; 45(9):1443-52. PubMed ID: 16131376
[TBL] [Abstract][Full Text] [Related]
6. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment.
Osselaer JC; Cazenave JP; Lambermont M; Garraud O; Hidajat M; Barbolla L; Tardivel R; Defoin L; Waller C; Mendel I; Raidot JP; Kandel G; De Meuter R; Fabrigli P; Dehenau D; Arroyo JL; Padrón F; Gouezec H; Corral M; Jacquet M; Sundin D; Lin L; Corash L
Vox Sang; 2008 May; 94(4):315-23. PubMed ID: 18248574
[TBL] [Abstract][Full Text] [Related]
7. Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study.
Simonsen AC; Johansson PI; Conlan MG; Jacquet M; Lin JS; Junge K; Lin L; Sørensen H; Borregaard N; Flament J
Transfusion; 2006 Mar; 46(3):424-33. PubMed ID: 16533286
[TBL] [Abstract][Full Text] [Related]
8. Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment.
Lin L; Conlan MG; Tessman J; Cimino G; Porter S
Transfusion; 2005 Oct; 45(10):1610-20. PubMed ID: 16181212
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light.
Wagner SJ; Skripchenko A; Myrup A; Awatefe H; Thompson-Montgomery D; Moroff G; Carmichael P; Lin L
Transfusion; 2009 Apr; 49(4):704-10. PubMed ID: 19171001
[TBL] [Abstract][Full Text] [Related]
10. Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions.
Lozano M; Galan A; Mazzara R; Corash L; Escolar G
Transfusion; 2007 Apr; 47(4):666-71. PubMed ID: 17381625
[TBL] [Abstract][Full Text] [Related]
11. Polymerase chain reaction inhibition assay documenting the amotosalen-based photochemical pathogen inactivation process of platelet concentrates.
Bruchmüller I; Janetzko K; Bugert P; Mayaudon V; Corash L; Lin L; Klüter H
Transfusion; 2005 Sep; 45(9):1464-72. PubMed ID: 16131379
[TBL] [Abstract][Full Text] [Related]
12. Photochemical treatment of platelet concentrates with amotosalen hydrochloride and ultraviolet A light inactivates free and latent cytomegalovirus in a murine transfusion model.
Jordan CT; Saakadze N; Newman JL; Lezhava LJ; Maiers TT; Hillyer WM; Roback JD; Hillyer CD
Transfusion; 2004 Aug; 44(8):1159-65. PubMed ID: 15265119
[TBL] [Abstract][Full Text] [Related]
13. Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1-month intravenous toxicity study in neonatal rats.
Ciaravino V; Hanover J; Lin L; Sullivan T; Corash L
Transfusion; 2009 May; 49(5):985-94. PubMed ID: 19175545
[TBL] [Abstract][Full Text] [Related]
14. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
[TBL] [Abstract][Full Text] [Related]
15. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria.
Lin L; Dikeman R; Molini B; Lukehart SA; Lane R; Dupuis K; Metzel P; Corash L
Transfusion; 2004 Oct; 44(10):1496-504. PubMed ID: 15383024
[TBL] [Abstract][Full Text] [Related]
16. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment.
Osselaer JC; Messe N; Hervig T; Bueno J; Castro E; Espinosa A; Accorsi P; Junge K; Jacquet M; Flament J; Corash L
Transfusion; 2008 Jun; 48(6):1061-71. PubMed ID: 18346019
[TBL] [Abstract][Full Text] [Related]
17. An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment.
Cazenave JP; Waller C; Kientz D; Mendel I; Lin L; Jacquet M; Propst M; Liu W; Corash L; Sundin D; Defoin L; Messe N; Osselaer JC
Transfusion; 2010 Jun; 50(6):1210-9. PubMed ID: 20113450
[TBL] [Abstract][Full Text] [Related]
18. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura.
Mintz PD; Neff A; MacKenzie M; Goodnough LT; Hillyer C; Kessler C; McCrae K; Menitove JE; Skikne BS; Damon L; Lopez-Plaza I; Rouault C; Crookston KP; Benjamin RJ; George J; Lin JS; Corash L; Conlan MG
Transfusion; 2006 Oct; 46(10):1693-704. PubMed ID: 17002625
[TBL] [Abstract][Full Text] [Related]
19. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light.
Snyder E; Raife T; Lin L; Cimino G; Metzel P; Rheinschmidt M; Baril L; Davis K; Buchholz DH; Corash L; Conlan MG
Transfusion; 2004 Dec; 44(12):1732-40. PubMed ID: 15584988
[TBL] [Abstract][Full Text] [Related]
20. Photochemical inactivation with amotosalen and long-wavelength ultraviolet light of Plasmodium and Babesia in platelet and plasma components.
Grellier P; Benach J; Labaied M; Charneau S; Gil H; Monsalve G; Alfonso R; Sawyer L; Lin L; Steiert M; Dupuis K
Transfusion; 2008 Aug; 48(8):1676-84. PubMed ID: 18503613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
